knowledge -WSS

knowledge

author：entertainment 2025-09-28 12:08:42 - browse：79282

The FDA building -- First Opinion coverage from STAT — Adobe

The Food and Drug Administration on Monday approved a gene therapy for metachromatic leukodystrophy, a devastating genetic disorder that eats away at affected children’s neurons.

The medicine, marketed as Lenmeldy, is the first treatment for MLD, which is otherwise fatal. Lenmeldy has to be given before symptoms appear or, in some cases, after the first signs of disease, so it won’t be helpful for many patients living with MLD today. But when given in time, it appears to be near-curative, allowing some children to grow up and attend school with unaffected peers.

Lenmeldy is already marketed in Europe, under the name Libmeldy, and has helped a handful of patients in the U.S. who were treated under compassionate use, as their doctors feared they didn’t have time to wait for approval.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Drug repurposing or repositioning? The language matters
Next article： Readout Newsletter: AstraZeneca's CEO, Roivant's $5 billion deal

WSS

STAT Summit: How researchers deal with rejection

Results on Novartis prostate cancer therapy could expand its use

PBMs drew scrutiny in House hearing — and so did pharma

How the messy conversation about Dolly changed bioethics

Harvard's Jason Buenrostro wins MacArthur grant for genetics work

Why a market frenzy over new weight loss drugs defies logic

explore

knowledge

focus

FDA approval of Sarepta Duchenne genetic therapy gives me hope

STAT Summit: Doctor v. ChatGPT showed AI's promise, blind spots

How one medical school became remarkably diverse

Covid’s new normal has set in amid another rise in cases

Jerome Adams on the need for new antivirals for Covid

David Liu startup to focus on CRISPR delivery

What does generative AI mean for health care? We asked experts

Why a market frenzy over new weight loss drugs defies logic

Dobbs anniversary: the lost opportunity of abortion as health care

People with substance use disorder deserve online privacy

hotspot

Patients, doctors press FTC to beef up hospital merger scrutiny

STAT Readout: Friday, Oct. 20 biotech updates

STAT Readout Newsletter: Biotech news today

Midwives could help bridge maternal health disparities in the U.S.

Neurocrine congenital adrenal hyperplasia trial succeeds

STAT Readout Newsletter: Biotech news today

leisure time

focus

entertainment

hotspot